Risk assets dip on the headline
Astrazeneca was in the news last week after a UK trial participant was hospitalized with side effects. The trial there resumed this week but it remains halted in the US as regulators there examine the case.
I can't see this derailing today's price action but there are some jitters at the moment with stocks at the lowest levels since the open.
